ICPT Key Statistics, Chart & Performance
The current stock price of ICPT is 19 USD. In the past month the price increased by 1.99%. In the past year, price increased by 17.94%.
ICPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About ICPT
Company Profile
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 341 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.
Company Info
INTERCEPT PHARMACEUTICALS IN
305 Madison Avenue
Morristown NEW JERSEY 10001 US
CEO: Jerome Durso
Employees: 341
Phone: 16467471000.0
INTERCEPT PHARMACEUTICALS IN / ICPT FAQ
What does INTERCEPT PHARMACEUTICALS IN do?
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Morristown, New Jersey and currently employs 341 full-time employees. The company went IPO on 2012-10-11. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. The firm is evaluating tolerability of OCA in combination with bezafibrate in patients with PBC in a Phase II study outside of the United States. Its other compounds are in early stages of research and development pipeline including INT-787 compound, an FXR agonist is in a Phase IIa clinical trial.
Can you provide the latest stock price for INTERCEPT PHARMACEUTICALS IN?
The current stock price of ICPT is 19 USD. The price increased by 0.21% in the last trading session.
Does INTERCEPT PHARMACEUTICALS IN pay dividends?
ICPT does not pay a dividend.
How is the ChartMill rating for INTERCEPT PHARMACEUTICALS IN?
ICPT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is INTERCEPT PHARMACEUTICALS IN (ICPT) expected to grow?
The Revenue of INTERCEPT PHARMACEUTICALS IN (ICPT) is expected to grow by 3.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of ICPT stock?
INTERCEPT PHARMACEUTICALS IN (ICPT) has a market capitalization of 794.39M USD. This makes ICPT a Small Cap stock.
ICPT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ICPT. When comparing the yearly performance of all stocks, ICPT is one of the better performing stocks in the market, outperforming 97.04% of all stocks.
ICPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ICPT. ICPT may be in some trouble as it scores bad on both profitability and health.
ICPT Financial Highlights
Over the last trailing twelve months ICPT reported a non-GAAP Earnings per Share(EPS) of -1.33. The EPS decreased by -125.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.67% | ||
| ROE | -85.76% | ||
| Debt/Equity | 3.12 |
ICPT Forecast & Estimates
20 analysts have analysed ICPT and the average price target is 19.38 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 19.
For the next year, analysts expect an EPS growth of -122.07% and a revenue growth 3.67% for ICPT